Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
- Diabetes Treatment
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 60836
The Licensor granted to us a royalty-bearing, exclusive right and license under and to patent rights and know how to make, use, market, commercialize, and offer for sale Non-Alcohol Docetaxel Injection described in NDA 205934.
Docetaxel is a taxane product indicated for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
Docetaxel Injection, Non-Alcohol formulation-Chemotherapeutic agent for Breast, non-small cell lung, prostate, head and neck cancers/ gastric adenocarcinoma
The agreement pertains to an investigational product in the drug industry intended for the treatment of various cancers.
IPSCIO Record ID: 242965
IPSCIO Record ID: 369384
For the Non-exclusive License, both Licensors grant to Licensee a non-exclusive, non-transferable license, under the other Licensors Know-How, including the right to sublicense, to research, develop, make, have made, use, offer for sale, sell and import Products, in each case solely within the Field and within the Territory.
Product means any one or more of the pharmaceutical product candidate known as ANX-514 (docetaxel emulsion) or any improvement or derivative thereof, or any product for which the manufacture, use, sale or importation is covered by a Valid Claim of the other Licensors Patents.
Patents include; Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof, and, Low oil emulsion compositions for delivering taxoids and other insoluble drugs.
ANX-514 is a reformulation of the blockbuster chemotherapeutic agent, TaxotereÂ®, an anti-cancer agent that is approved to treat breast, non-small cell lung, prostate, head and neck and gastric cancers.
ANX-514 is a novel nano-emulsion formulation of the chemotherapy drug docetaxel, a formulation of which is marketed under the brand name Taxotere. ANX-514 is formulated without polysorbate 80 or other detergents and is intended to reduce the severity and/or incidence of hypersensitivity reactions. Docetaxel is an anti-cancer agent that acts by disrupting the cellular microtubular network that is essential for cell division. Immunosuppressant premedication is recommended for docetaxel therapy to reduce the incidence and severity of hypersensitivity reactions. Docetaxel is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers.
The Field means the treatment of cancer by intravenous administration of formulations of
docetaxel as emulsified products.
IPSCIO Record ID: 256273
This agreement includes a non-exclusive grant by Licensee to Licensor.
The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.
Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.
IPSCIO Record ID: 256873
The new drug products that originate from Maitake Combination Therapy. The three drugs licensed from BriVision to Rgene are ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy.
IPSCIO Record ID: 325366
Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. The main subtypes of NSCLC Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
IPSCIO Record ID: 238987
The Canadian Licensor grants to Licensee an exclusive sublicense, even as against the Licensor, under the Patent Rights to develop and have developed, market and have marketed, sell and have sold, distribute and have distributed, and manufacture and have manufactured, the Licensed Products in the Territory, said license to include the right to further sub-license.
Licensed Product shall mean anhydrovinblastine sulfate (AVLB), with the chemical name 3 ,4 – dehydrovinblastine sulphate and molecular formula C4Jls~40s-H2SO4â€¢.
KRX-0403 is a novel spindle poison in the vinca alkaloid class of drugs. Derived from the periwinkle plant, the family of vinca alkaloids and the mechanistically similar family of taxanes include some of the most successful cancer drugs ever developed, including NavelbineÂ®, TaxolÂ® and TaxotereÂ®. Although these agents have been widely prescribed, they can be very toxic and may cause varying degrees of neurotoxicity and/or bone marrow suppression. We believe that an equally or more effective but less toxic therapy would satisfy a substantial need for these patients. In a number of pre-clinical animal studies of human cancers, including non-small cell lung cancer, KRX-0403 demonstrated greater anti-cancer activity and lower toxicity than currently marketed vinca alkaloids. In a Phase I clinical trial designed to evaluate the safety, toxicity profile and pharmacokinetics of KRX-0403 in patients with different tumor types, including lung cancer, breast cancer, sarcoma and colon cancer, KRX-0403 was demonstrated to be safe in humans with reversible and manageable toxicities. We believe KRX-0403 may have utility in the treatment of breast, lung and other forms of cancer. We plan to conduct additional dosing clinical trials for KRX-0403.
IPSCIO Record ID: 29382
The Company manufactures its bulk requirements for ixabepilone in its own facilities including the manufacturing of the active ingredient. The drug product which comprises a pharmaceutical kit is finished by Baxter Oncology GmbH.